Advertisement

Diabetology International

, Volume 7, Issue 2, pp 133–140 | Cite as

Complementary glucagonostatic and insulinotropic effects of DPP-4 inhibitors in the glucose-lowering action in Japanese patients with type 2 diabetes

  • Ken-ichi Hashimoto
  • Yukio HorikawaEmail author
  • Jun Takeda
Original Article
  • 215 Downloads

Abstract

The dipeptidyl peptidase-4 (DPP-4) inhibitors have a low risk of causing hypoglycemia as monotherapy. However, insulin administration is frequently required, particularly in patients with type 2 diabetes and with reduced insulin secretory capacity. The effects of adding DPP-4 inhibitors were evaluated using continuous glucose monitoring (CGM) in Japanese patients with type 2 diabetes who were insufficiently controlled by basal insulin with biguanide. The effects of adding DPP-4 inhibitors on blood glucose and plasma insulin and glucagon levels were evaluated. Δ glucagon showed a significant association with post-prandial glucose increase in the group with diminished insulin secretory capacity, C-peptide index (CPI) <0.8 (p = 0.016), while Δ C-peptide reached significant association in the group with relatively intact insulin secretory capacity, CPI ≥0.8 (p = 0.017). The mean plasma glucose levels and M values were similarly improved in patients treated with the three DPP-4 inhibitors. Hypoglycemia did not occur in any of the DPP-4 inhibitor groups. In conclusion, complementary glucagonostatic and insulinotropic effects of adding DPP-4 inhibitors are involved in the glucose-lowering action of Japanese patients with type 2 diabetes according to their insulin secretory capacity. Such combination therapy may well be a superior therapeutic option for the treatment of diabetes in Japanese patients who often exhibit reduced insulin secretory capacity.

Keywords

Type 2 diabetes mellitus DPP-4 inhibitors Hypoglycemia Glucagon Insulin 

Abbreviations

DPP-4

Dipeptidyl peptidase-4

CGM

Continuous glucose monitoring

BOT

Basal supported oral therapy

SUIT

Secretory units of islets in transplantation

CPI

C-peptide index

GLP-1

Glucagon like peptide-1

GIP

Glucose-dependent insulinotropic polypeptide

FPG

Fasting plasma glucose

PPG

Postprandial plasma glucose

CPR

C-peptide immunoreactivity

IRG

Immunoreactive glucagon

ANOVA

Analysis of variance

NPH

Neutral protamine hagedorn

Notes

Acknowledgement

We thank the patients for their kind contribution to this study. This work was supported by a Grant-in-Aid for Scientific Research from the Japanese Ministry of Science, Education, Sports, Culture, and Technology (No.25293228, 26293246).

Compliance with ethical standards

Conflict of interest

YH received honoraria for lectures from Astellas Pharma Inc. and scholarship grants from MSD. JT received honoraria for lectures from Astellas Pharma Inc., Sanofi K.K, Ono Pharmaceutical Co. Ltd., Novo Nordisk Pharma Ltd., Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., MSD., Dainippon Sumitomo Pharma Co.,Ltd., Mitsubishi Tanabe Pharma Corporation, Boehringer Ingelheim, Taisho Toyama Pharmaceutical Co.Ltd. and Kowa Company, Ltd., and scholarship grants from Boehringer Ingelheim, Sanofi K.K, Ono Pharmaceutical Co. Ltd., Novo Nordisk Pharma Ltd., Novartis Pharma K.K., Sanwa Kagaku Kenkyusho Co., Ltd., Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Eli Lilly Japan K.K. Taisho Toyama Pharmaceutical Co.Ltd., MSD., Kowa Company, Ltd. and Kyowa Hakko Kirin Co.Ltd. K.H declares that he has no conflict of interest.

Human rights statement and informed consent

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later revision. Informed consent or substitute for it was obtained from all patients for being included in the study.

References

  1. 1.
    Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract. 2004;66(suppl 1):S37–43.CrossRefPubMedGoogle Scholar
  2. 2.
    Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357:1716–30.CrossRefPubMedGoogle Scholar
  3. 3.
    Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301:1565–72.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Car. 2006;29:554–9.CrossRefGoogle Scholar
  5. 5.
    Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153–65.CrossRefPubMedGoogle Scholar
  6. 6.
    Meigs JB, Nathan DM, D’Agostino RB Sr, Wilson PW. Framingham Offspring Study. Fasting and post-challenge glycemia and cardiovascular disease risk: the Framingham offspring study. Diabetes Car. 2002;25:1845–50.CrossRefGoogle Scholar
  7. 7.
    Yamada Y, Fukuda K, Fujimoto S, et al. SUIT, secretory units of islets in transplantation: an index for therapeutic management of islet transplanted patients and its application to type 2 diabetes. Diabetes Res Clin Pract. 2006;74:222–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Iwata M, Matsushita Y, Fukuda K, et al. Secretory units of islets in transplantation index is a useful predictor of insulin requirement in Japanese type 2 diabetic patients. J Diabetes Investig. 2014;5:570–80.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Funakoshi S, Fujimoto S, Hamasaki A, et al. Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes. J Diabetes Investig. 2011;2:297–303.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Klonoff DC. Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Car. 2005;28:1231–9.CrossRefGoogle Scholar
  11. 11.
    Service FJ. Glucose variability. Diabetes. 2013;62:1398–404.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Takahara M, Shiraiwa T, Kaneto H, Katakami N, Matsuoka TA, Shimomura I. Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy. Endocr J. 2012;59:1131–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomized controlled trial. Lancet. 2008;371:1073–84.CrossRefPubMedGoogle Scholar
  14. 14.
    Kielgast U, Holst JJ, Madsbad S. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function. Diabetes. 2011;60:1599–607.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Vollmer K, Gardiwal H, Menge BA, et al. Hyperglycemia acutely lowers the postprandial excursions of glucagon-like peptide-1 and gastric inhibitory polypeptide in humans. J Clin Endocrinol Metab. 2009;94:1379–85.CrossRefPubMedGoogle Scholar
  16. 16.
    Basu R, Breda E, Oberg AL, et al. Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance. Diabetes. 2003;52:1738–48.CrossRefPubMedGoogle Scholar
  17. 17.
    Wahl PW, Savage PJ, Psaty BM, Orchard TJ, Robbins JA, Tracy RP. Diabetes in older adults: comparison of 1997 American Diabetes Association classification of diabetes mellitus with 1985 WHO classification. Lancet. 1998;352:1012–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH. Glucagon receptor knockout prevents insulin deficient type 1 diabetes in mice. Diabetes. 2011;60:391–7.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Migoya EM, Bergeron R, Miller JL, et al. Dipeptidyl peptidase-4 inhibitor administered in combination with metformin results in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther. 2010;88:801–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature. 2013;494:256–60.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Hare KJ, Vilsbøll T, Asmar M, Deacon CF, Knop FK, Holst JJ. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes. 2010;59:1765–70.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705.CrossRefPubMedGoogle Scholar
  23. 23.
    Kim SA, Shim WH, Lee EH, et al. Predictive clinical parameters for the therapeutic efficacy of sitagliptin in Korean type 2 diabetes mellitus. Diabetes Metab. J. 2011;35:159–65.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Nakamura A, Terauchi Y. Factors associated with the glucose lowering effect of vildagliptin identified from the results of the oral glucose tolerance test in Japanese patients with type 2 diabetes. Endocr J. 2013;60:45–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Sathanantham A, Man CD, Micheletto F, et al. Common genetic variation in GLP-1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subject: a pilot study. Diabetes Care. 2010;33:2074–6.CrossRefGoogle Scholar
  26. 26.
    Iwasaki M, Hoshian F, Tsuji T, et al. Predicting efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels. J Diabetes Invest. 2012;3:464–7.CrossRefGoogle Scholar
  27. 27.
    Johnston SS, Conner C, Aagren M, Smith DM, Bouchard J, Brett J. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Car. 2011;34:1164–70.CrossRefGoogle Scholar
  28. 28.
    Aung PP, Strachan MW, Frier BM, Butcher I, Deary IJ, Price JF. Edinburgh type 2 diabetes study investigators. severe hypoglycaemia and late-life cognitive ability in older people with Type 2 diabetes: the edinburgh type 2 diabetes study. Diabet Med. 2012;29:328–36.CrossRefPubMedGoogle Scholar
  29. 29.
    Chelliah A, Burge MR. Hypoglycemia in elderly patient with diabetes mellitus. Causes and strategies for prevention. Drugs Aging. 2004;21:511–30.CrossRefPubMedGoogle Scholar
  30. 30.
    Ryan MT, Savarese VW, Hipszer B, et al. Continuous glucose monitor shows potential for early hypoglycemia detection in hospitalized patients. Diabetes Technol. Ther. 2009;11:745–7.CrossRefPubMedGoogle Scholar

Copyright information

© The Japan Diabetes Society 2015

Authors and Affiliations

  • Ken-ichi Hashimoto
    • 1
  • Yukio Horikawa
    • 1
    Email author
  • Jun Takeda
    • 1
  1. 1.Department of Diabetes and EndocrinologyGifu University Graduate School of MedicineGifuJapan

Personalised recommendations